Open Access Open Access  Restricted Access Subscription or Fee Access

“Study on Pharmaco-Genomics of Targated Anti-Cancer Therapy”

Kumari Niharika, Dutta Amit Kumar

Abstract


Abstract

Pharmacogenomics is a stream of pharmacology which deals with the study of how genes affect a person’s response to drugs. The term pharmacology (the study of drugs) and genomics (the study of genes and their functions) leads to Pharmacogenomics, therefore means the study of drugs on genes in targeted treatment of cancer. Cancer is abnormal and uncontrolled growth of cells in the body. The cell growth is uncontrolled and uneven replication occurs and leads to the tumor formation and this is due to the alteration of the genetic sequence to the cells. Cancer cell can be differentiated from normal cells by the cell growth determination. The normal cells grow at a constant rate and appear in normal in nature and divide in an even number, but cancer cells replicate at a phenomenal rate. Targeted therapies are advance treatment options are with biomolecules with patients. The patients require very accurate testing to monitor the compatibility with the drug. Each patient responds differently to the drugs, so the drugs are administered according to the patient. There are commonly two types of therapies named as monoclonal antibodies and small molecule drugs. These two drugs are more effective as compared to other targeted therapies.


Keywords


Pharmacogenomics, Cancer cell line, Targeted drug, Biomolecules, Antibodies, Comparative analysis

Full Text:

PDF

References


Clarke Brian Blackadar. Historical review of the causes of cancer, World Journal of Clinical Oncology 2016; 7 (1): 54–86.

ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2010; 79(1): 63–74.

Michael Brown, Carl Wittwer. Flow Cytometry: Principles and Clinical Applications in Hematology. Clinical Chemistry 2000; 46 (8): 1221–1229.

Rotili D, Mai A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer 2011; 2 (6): 663–79.

Meyer, U.A., 2004. Pharmacogenetics–five decades of therapeutic lessons from genetic diversity. Nature Reviews Genetics, 5 (9), pp. 669–676.

Evans, W.E. and Relling, M.V., 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. science, 286 (5439), pp. 487–491.

McDermott, U., Downing, J.R. and Stratton, M.R., 2011. Genomics and the continuum of cancer care. New England Journal of Medicine, 364 (4), pp. 340–350.

Stratton, M.R., Campbell, P.J. and Futreal, P.A., 2009. The cancer genome. Nature, 458 (7239), pp. 719–724.

Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordóñez, G.R., Bignell, G.R. and Ye, K., 2010. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463 (7278), pp. 191–196.

uang, Y.T., Heist, R.S., Chirieac, L.R., Lin, X., Skaug, V., Zienolddiny, S., Haugen, A., Wu, M.C., Wang, Z., Su, L. and Asomaning, K., 2009. Genome-wide analysis of survival in early-stage non–small-cell lung cancer. Journal of clinical oncology, 27 (16), p. 2660.

Zhang, Y., Martens, J.W., Jack, X.Y., Jiang, J., Sieuwerts, A.M., Smid, M., Klijn, J.G., Wang, Y. and Foekens, J.A., 2009. Copy number alterations that predict metastatic capability of human breast cancer. Cancer research, 69 (9), pp. 3795–3801.

Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D.S., 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366 (1), pp. 2–16.

Raymond, E., Faivre, S. and Armand, J.P., 2000. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs, 60 (1), pp. 15–23.

Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31–53.

Krause, D.S. and Van Etten, R.A., 2005. Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine, 353 (2), pp. 172–187.

De Witt Hamer, P.C., 2010. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-oncology, 12 (3), pp. 304–316.

Campone, M., Berton-Rigaud, D., Bourbouloux, E., Sophie, S., Zanetti, A. and Frenel, J.S., 2011. Les cancers du sein HER2: que devons-nous retenir dans notre pratique clinique quotidienne?. Bulletin du cancer, 98 (2), pp. 154–163.


Refbacks

  • There are currently no refbacks.